Effectiveness of Phosphodiesterase-5 Inhibitor Therapy for Portopulmonary Hypertension
BACKGROUND: Portopulmonary hypertension is associated with significant morbidity and mortality. Phosphodiesterase-5 inhibitor therapy is efficacious in other causes of WHO group I pulmonary arterial hypertension.
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2015-01-01
|
Series: | Canadian Respiratory Journal |
Online Access: | http://dx.doi.org/10.1155/2015/810376 |